SGLT2 Inhibitors in Patients With Cancer Therapy-Related Cardiotoxicity: An Unexpected Benefit?

JACC. Heart failure

Authors	Ohad Oren Pradeep Natarajan Deepak Bhatt
Keywords	SGLT2 inhibitors cancer cardio-oncology cardio-toxicity Heart Failure
Year of Publication	2024
Journal	JACC. Heart failure
Volume	12
Issue	1
Pages	79-82
Date Published	01/2024
ISSN	2213-1787
DOI	10.1016/j.jchf.2023.10.005
PubMed ID	37999662
Links	DOI PubMed Google Scholar

Recent Broad Publications

Hope on the Horizon: A Revolution in KRAS Inhibition Is Creating a New Treatment Paradigm for Patients with Pancreatic Cancer.

Metabolomics of IgE-Mediated Food Allergy and Oral Immunotherapy Outcomes based on Metabolomic Profiling.

Platelet integrin αIIbβ3 plays a key role in venous thrombogenesis in a mouse model.

Genetic Architecture and Analysis Practices of Circulating Metabolites in the NHLBI Trans-Omics for Precision Medicine (TOPMed) Program.

The glycolytic reaction PGAM unexpectedly restrains Th17 pathogenicity and Th17-dependent autoimmunity.